Innate Pharma(IPHA)
$1.59+0.05 (+3.31%)
IPHA
Innate Pharma financials statements
$1.59
At close:+0.05 (+3.31%)
Want to see IPHA full AI Analyst Report?
Innate Pharma (IPHA) Financial Statements
155 Followers
Innate Pharma Financial Overview
Innate Pharma's market cap is currently €163.61M. The company's EPS TTM is €-0.51; its P/E ratio is -2.72; Innate Pharma is estimated to report earnings on March 25, 2027, and the estimated EPS forecast is €-0.11. See an overview of income statement, balance sheet, and cash flow financials.
| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | € 2.79M | € 12.62M | € 51.90M | € 57.67M | € 12.11M |
| Gross Profit | € 2.79M | € 12.62M | € 5.62M | € 6.01M | € -22.30M |
| Operating Income | € -53.42M | € -51.58M | € -12.67M | € -57.42M | € -47.83M |
| EBITDA | € -43.65M | € -46.91M | € -1.84M | € -12.28M | € -43.23M |
| Net Income | € -49.18M | € -49.47M | € -7.57M | € -58.10M | € -52.81M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | € 34.30M | € 80.77M | € 92.46M | € 101.48M | € 119.84M |
| Total Assets | € 62.69M | € 111.06M | € 175.19M | € 207.86M | € 267.50M |
| Total Debt | € 22.56M | € 31.00M | € 39.89M | € 42.25M | € 44.25M |
| Net Debt | € -5.52M | € -35.40M | € -30.71M | € -41.97M | € -59.51M |
| Total Liabilities | € 84.39M | € 102.22M | € 132.29M | € 153.71M | € 160.06M |
| Stockholders' Equity | € -21.69M | € 8.83M | € 51.90M | € 54.15M | € 107.44M |
| Cash Flow | |||||
| Free Cash Flow | € -34.91M | € -7.29M | € -32.91M | € -20.28M | € -59.39M |
| Operating Cash Flow | € -32.56M | € -6.90M | € -32.56M | € -19.15M | € -58.46M |
| Investing Cash Flow | € 20.63M | € 9.20M | € 20.63M | € 1.88M | € -917.00K |
| Financing Cash Flow | € -1.97M | € -6.01M | € -1.97M | € -1.83M | € 26.82M |
Currency in EUR
